Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 206 entries
Sorted by: Best Match Show Resources per page
Hepatitis C virus-related glomerulonephritis with acute kidney injury requiring hemodialysis that improved with virus removal and eradication using double-filtration plasmapheresis without interferon.

CEN case reports

Morisue A, Fukuoka K, Goto R, Ota K, Yamashita H, Shinno Y, Yamadori I.
PMID: 28509265
CEN Case Rep. 2015 May;4(1):38-42. doi: 10.1007/s13730-014-0136-z. Epub 2014 Jul 15.

A 66-year-old, hepatitis C virus (HCV)-positive woman was admitted to our hospital with oliguria, systemic edema, and rapid deterioration of renal function. Laboratory examination showed increased serum creatinine and decreased serum albumin levels, complement activity, and cryoglobulin positivity. The...

Cite
Morisue A, Fukuoka K, Goto R, et al. Hepatitis C virus-related glomerulonephritis with acute kidney injury requiring hemodialysis that improved with virus removal and eradication using double-filtration plasmapheresis without interferon. CEN Case Rep. 2014;4(1):38-42doi: 10.1007/s13730-014-0136-z.
Morisue, A., Fukuoka, K., Goto, R., Ota, K., Yamashita, H., Shinno, Y., & Yamadori, I. (2015). Hepatitis C virus-related glomerulonephritis with acute kidney injury requiring hemodialysis that improved with virus removal and eradication using double-filtration plasmapheresis without interferon. CEN case reports, 4(1), 38-42. https://doi.org/10.1007/s13730-014-0136-z
Morisue, Akiko, et al. "Hepatitis C virus-related glomerulonephritis with acute kidney injury requiring hemodialysis that improved with virus removal and eradication using double-filtration plasmapheresis without interferon." CEN case reports vol. 4,1 (2015): 38-42. doi: https://doi.org/10.1007/s13730-014-0136-z
Morisue A, Fukuoka K, Goto R, Ota K, Yamashita H, Shinno Y, Yamadori I. Hepatitis C virus-related glomerulonephritis with acute kidney injury requiring hemodialysis that improved with virus removal and eradication using double-filtration plasmapheresis without interferon. CEN Case Rep. 2015 May;4(1):38-42. doi: 10.1007/s13730-014-0136-z. Epub 2014 Jul 15. PMID: 28509265; PMCID: PMC5413711.
Copy Download .nbib Format: NLM
Prognostic value of matrix metalloproteinase-9 expression in oral squamous cell carcinoma and its association with angiogenesis.

Journal of clinical and experimental dentistry

Andisheh-Tadbir A, Mardani M, Pourshahidi S, Nezarati K, Bahadori P.
PMID: 27034751
J Clin Exp Dent. 2016 Apr 01;8(2):e130-5. doi: 10.4317/jced.52712. eCollection 2016 Apr.

BACKGROUND: Breakdown of extracellular matrix (ECM) is one of the important hallmarks of cancer progression which facilitates the invasion of tumoral cells to the surrounding tissue. Matrix metalloproteinases (MMPs) can degrade various components of the ECM and basement membrane....

Cite
Andisheh-Tadbir A, Mardani M, Pourshahidi S, et al. Prognostic value of matrix metalloproteinase-9 expression in oral squamous cell carcinoma and its association with angiogenesis. J Clin Exp Dent. 2016;8(2):e130-5doi: 10.4317/jced.52712.
Andisheh-Tadbir, A., Mardani, M., Pourshahidi, S., Nezarati, K., & Bahadori, P. (2016). Prognostic value of matrix metalloproteinase-9 expression in oral squamous cell carcinoma and its association with angiogenesis. Journal of clinical and experimental dentistry, 8(2), e130-5. https://doi.org/10.4317/jced.52712
Andisheh-Tadbir, Azadeh, et al. "Prognostic value of matrix metalloproteinase-9 expression in oral squamous cell carcinoma and its association with angiogenesis." Journal of clinical and experimental dentistry vol. 8,2 (2016): e130-5. doi: https://doi.org/10.4317/jced.52712
Andisheh-Tadbir A, Mardani M, Pourshahidi S, Nezarati K, Bahadori P. Prognostic value of matrix metalloproteinase-9 expression in oral squamous cell carcinoma and its association with angiogenesis. J Clin Exp Dent. 2016 Apr 01;8(2):e130-5. doi: 10.4317/jced.52712. eCollection 2016 Apr. PMID: 27034751; PMCID: PMC4808306.
Copy Download .nbib Format: NLM
Association between Attention and Heart Rate Fluctuations in Pathological Worriers.

Frontiers in human neuroscience

Gazzellini S, Dettori M, Amadori F, Paoli B, Napolitano A, Mancini F, Ottaviani C.
PMID: 28082881
Front Hum Neurosci. 2016 Dec 27;10:648. doi: 10.3389/fnhum.2016.00648. eCollection 2016.

Recent data suggests that several psychopathological conditions are associated with alterations in the variability of behavioral and physiological responses. Pathological worry, defined as the cognitive representation of a potential threat, has been associated with reduced variability of heart beat...

Cite
Gazzellini S, Dettori M, Amadori F, et al. Association between Attention and Heart Rate Fluctuations in Pathological Worriers. Front Hum Neurosci. 2016;10:648doi: 10.3389/fnhum.2016.00648.
Gazzellini, S., Dettori, M., Amadori, F., Paoli, B., Napolitano, A., Mancini, F., & Ottaviani, C. (2016). Association between Attention and Heart Rate Fluctuations in Pathological Worriers. Frontiers in human neuroscience, 10648. https://doi.org/10.3389/fnhum.2016.00648
Gazzellini, Simone, et al. "Association between Attention and Heart Rate Fluctuations in Pathological Worriers." Frontiers in human neuroscience vol. 10 (2016): 648. doi: https://doi.org/10.3389/fnhum.2016.00648
Gazzellini S, Dettori M, Amadori F, Paoli B, Napolitano A, Mancini F, Ottaviani C. Association between Attention and Heart Rate Fluctuations in Pathological Worriers. Front Hum Neurosci. 2016 Dec 27;10:648. doi: 10.3389/fnhum.2016.00648. eCollection 2016. PMID: 28082881; PMCID: PMC5187380.
Copy Download .nbib Format: NLM
Important factors for achieving survival of five years or more in non-small cell lung cancer patients with distant metastasis.

Oncology letters

Hirashima T, Suzuki H, Okamoto N, Morishita N, Yamadori T, Tamiya M, Shiroyama T, Kurata K, Kawase I.
PMID: 24959271
Oncol Lett. 2014 Jul;8(1):327-334. doi: 10.3892/ol.2014.2107. Epub 2014 Apr 30.

In order to examine which factors were important for achieving a ≥5 year survival time in non-small cell lung cancer (NSCLC) patients with distant metastasis, 268 NSCLC patients who received first-line chemotherapy between January 2004 and December 2007 were...

Cite
Hirashima T, Suzuki H, Okamoto N, et al. Important factors for achieving survival of five years or more in non-small cell lung cancer patients with distant metastasis. Oncol Lett. 2014;8(1):327-334doi: 10.3892/ol.2014.2107.
Hirashima, T., Suzuki, H., Okamoto, N., Morishita, N., Yamadori, T., Tamiya, M., Shiroyama, T., Kurata, K., & Kawase, I. (2014). Important factors for achieving survival of five years or more in non-small cell lung cancer patients with distant metastasis. Oncology letters, 8(1), 327-334. https://doi.org/10.3892/ol.2014.2107
Hirashima, Tomonori, et al. "Important factors for achieving survival of five years or more in non-small cell lung cancer patients with distant metastasis." Oncology letters vol. 8,1 (2014): 327-334. doi: https://doi.org/10.3892/ol.2014.2107
Hirashima T, Suzuki H, Okamoto N, Morishita N, Yamadori T, Tamiya M, Shiroyama T, Kurata K, Kawase I. Important factors for achieving survival of five years or more in non-small cell lung cancer patients with distant metastasis. Oncol Lett. 2014 Jul;8(1):327-334. doi: 10.3892/ol.2014.2107. Epub 2014 Apr 30. PMID: 24959271; PMCID: PMC4063572.
Copy Download .nbib Format: NLM
Treatment of acute myeloid leukemia with 20-30% bone marrow blasts.

Mediterranean journal of hematology and infectious diseases

Maurillo L, Buccisano F, Del Principe MI, Sarlo C, Di Caprio L, Ditto C, Giannotti F, Nasso D, Ceresoli E, Postorino M, Refrigeri M, Amadori S, Venditti A.
PMID: 23795270
Mediterr J Hematol Infect Dis. 2013 Jun 03;5(1):e2013032. doi: 10.4084/MJHID.2013.032. Print 2013.

The transition of patients with ≥20% 30% BM blast. These controversies are even more manifest when it comes to elderly patients in whom concern for intensive chemotherapy (IC) related toxicity is the critical determinant for the therapeutic choice. In...

Cite
Maurillo L, Buccisano F, Del Principe MI, et al. Treatment of acute myeloid leukemia with 20-30% bone marrow blasts. Mediterr J Hematol Infect Dis. 2013;5(1):e2013032doi: 10.4084/MJHID.2013.032.
Maurillo, L., Buccisano, F., Del Principe, M. I., Sarlo, C., Di Caprio, L., Ditto, C., Giannotti, F., Nasso, D., Ceresoli, E., Postorino, M., Refrigeri, M., Amadori, S., & Venditti, A. (2013). Treatment of acute myeloid leukemia with 20-30% bone marrow blasts. Mediterranean journal of hematology and infectious diseases, 5(1), e2013032. https://doi.org/10.4084/MJHID.2013.032
Maurillo, Luca, et al. "Treatment of acute myeloid leukemia with 20-30% bone marrow blasts." Mediterranean journal of hematology and infectious diseases vol. 5,1 (2013): e2013032. doi: https://doi.org/10.4084/MJHID.2013.032
Maurillo L, Buccisano F, Del Principe MI, Sarlo C, Di Caprio L, Ditto C, Giannotti F, Nasso D, Ceresoli E, Postorino M, Refrigeri M, Amadori S, Venditti A. Treatment of acute myeloid leukemia with 20-30% bone marrow blasts. Mediterr J Hematol Infect Dis. 2013 Jun 03;5(1):e2013032. doi: 10.4084/MJHID.2013.032. Print 2013. PMID: 23795270; PMCID: PMC3684350.
Copy Download .nbib Format: NLM
Comparison of the therapeutic effects of the dietary and topical forms of Zizyphus jujuba extract on oral mucositis induced by 5-fluorouracil: A golden hamster model.

Journal of clinical and experimental dentistry

Koohi-Hosseinabadi O, Andisheh-Tadbir A, Bahadori P, Sepehrimanesh M, Mardani M, Tanideh N.
PMID: 26155351
J Clin Exp Dent. 2015 Apr 01;7(2):e304-9. doi: 10.4317/jced.52198. eCollection 2015 Apr.

BACKGROUND: Oral mucositis (OM) is a common inflammatory complication among cancerous patients as an adverse effect of chemotherapy and radiotherapy. The aim of this study was to evaluate the effects and identify the appropriate route of administration of extract...

Cite
Koohi-Hosseinabadi O, Andisheh-Tadbir A, Bahadori P, et al. Comparison of the therapeutic effects of the dietary and topical forms of Zizyphus jujuba extract on oral mucositis induced by 5-fluorouracil: A golden hamster model. J Clin Exp Dent. 2015;7(2):e304-9doi: 10.4317/jced.52198.
Koohi-Hosseinabadi, O., Andisheh-Tadbir, A., Bahadori, P., Sepehrimanesh, M., Mardani, M., & Tanideh, N. (2015). Comparison of the therapeutic effects of the dietary and topical forms of Zizyphus jujuba extract on oral mucositis induced by 5-fluorouracil: A golden hamster model. Journal of clinical and experimental dentistry, 7(2), e304-9. https://doi.org/10.4317/jced.52198
Koohi-Hosseinabadi, Omid, et al. "Comparison of the therapeutic effects of the dietary and topical forms of Zizyphus jujuba extract on oral mucositis induced by 5-fluorouracil: A golden hamster model." Journal of clinical and experimental dentistry vol. 7,2 (2015): e304-9. doi: https://doi.org/10.4317/jced.52198
Koohi-Hosseinabadi O, Andisheh-Tadbir A, Bahadori P, Sepehrimanesh M, Mardani M, Tanideh N. Comparison of the therapeutic effects of the dietary and topical forms of Zizyphus jujuba extract on oral mucositis induced by 5-fluorouracil: A golden hamster model. J Clin Exp Dent. 2015 Apr 01;7(2):e304-9. doi: 10.4317/jced.52198. eCollection 2015 Apr. PMID: 26155351; PMCID: PMC4483342.
Copy Download .nbib Format: NLM
Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy.

Leukemia research and treatment

Sarlo C, Buccisano F, Maurillo L, Cefalo M, Di Caprio L, Cicconi L, Ditto C, Ottaviani L, Di Veroli A, Del Principe MI, Grasso MA, Nasso D, De Santis G, Amadori S, Venditti A.
PMID: 23738080
Leuk Res Treatment. 2013;2013:705714. doi: 10.1155/2013/705714. Epub 2013 Apr 28.

We explored the safety and efficacy of bortezomib given as single agent in patients with untreated or relapsed/refractory acute myeloid leukemia (AML), unfit for conventional chemotherapy. Fourteen patients were treated with bortezomib 1.5 mg/m(2) administered twice weekly for two...

Cite
Sarlo C, Buccisano F, Maurillo L, et al. Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy. Leuk Res Treatment. 2013;2013:705714doi: 10.1155/2013/705714.
Sarlo, C., Buccisano, F., Maurillo, L., Cefalo, M., Di Caprio, L., Cicconi, L., Ditto, C., Ottaviani, L., Di Veroli, A., Del Principe, M. I., Grasso, M. A., Nasso, D., De Santis, G., Amadori, S., & Venditti, A. (2013). Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy. Leukemia research and treatment, 2013705714. https://doi.org/10.1155/2013/705714
Sarlo, Chiara, et al. "Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy." Leukemia research and treatment vol. 2013 (2013): 705714. doi: https://doi.org/10.1155/2013/705714
Sarlo C, Buccisano F, Maurillo L, Cefalo M, Di Caprio L, Cicconi L, Ditto C, Ottaviani L, Di Veroli A, Del Principe MI, Grasso MA, Nasso D, De Santis G, Amadori S, Venditti A. Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy. Leuk Res Treatment. 2013;2013:705714. doi: 10.1155/2013/705714. Epub 2013 Apr 28. PMID: 23738080; PMCID: PMC3655652.
Copy Download .nbib Format: NLM
Granulomatous Hepatitis preceding Hodgkin's Disease (Case-Report and Review on Differential Diagnosis).

Pathology oncology research : POR

Bergter W, Fetzer IC, Sattler B, Ramadori G.
PMID: 11173603
Pathol Oncol Res. 1996;2(3):177-180. doi: 10.1007/BF02903523.

Granulomas are a frequent finding in various organs with a wide range of causes. Hepatic granulomas most often occur in the course of sarcoidosis or tuberculosis. However, they also may develop during Hodgkin's disease or sometimes even precede lymphoma...

Cite
Bergter W, Fetzer IC, Sattler B, et al. Granulomatous Hepatitis preceding Hodgkin's Disease (Case-Report and Review on Differential Diagnosis). Pathol Oncol Res. 1996;2(3):177-180doi: 10.1007/BF02903523.
Bergter, W., Fetzer, I. C., Sattler, B., & Ramadori, G. (1996). Granulomatous Hepatitis preceding Hodgkin's Disease (Case-Report and Review on Differential Diagnosis). Pathology oncology research : POR, 2(3), 177-180. https://doi.org/10.1007/BF02903523
Bergter, Wolfgang, et al. "Granulomatous Hepatitis preceding Hodgkin's Disease (Case-Report and Review on Differential Diagnosis)." Pathology oncology research : POR vol. 2,3 (1996): 177-180. doi: https://doi.org/10.1007/BF02903523
Bergter W, Fetzer IC, Sattler B, Ramadori G. Granulomatous Hepatitis preceding Hodgkin's Disease (Case-Report and Review on Differential Diagnosis). Pathol Oncol Res. 1996;2(3):177-180. doi: 10.1007/BF02903523. PMID: 11173603.
Copy Download .nbib Format: NLM
Proteomic analysis of autoantigens associated with systemic lupus erythematosus: Anti-aldolase A antibody as a potential marker of lupus nephritis.

Proteomics. Clinical applications

Serada S, Fujimoto M, Takahashi T, He P, Hayashi A, Tanaka T, Hagihara K, Yamadori T, Mochizuki M, Norioka N, Norioka S, Kawase I, Naka T.
PMID: 21136668
Proteomics Clin Appl. 2007 Feb;1(2):185-91. doi: 10.1002/prca.200600497. Epub 2007 Jan 22.

To screen for autoantibodies associated with systemic lupus erythematosus (SLE), we used proteomic approaches combining 2-D PAGE and Western blot analysis, followed by protein identification by LC-MS/MS analysis, resulting in the identification of aldolase A as a novel autoantigen...

Cite
Serada S, Fujimoto M, Takahashi T, et al. Proteomic analysis of autoantigens associated with systemic lupus erythematosus: Anti-aldolase A antibody as a potential marker of lupus nephritis. Proteomics Clin Appl. 2007;1(2):185-91doi: 10.1002/prca.200600497.
Serada, S., Fujimoto, M., Takahashi, T., He, P., Hayashi, A., Tanaka, T., Hagihara, K., Yamadori, T., Mochizuki, M., Norioka, N., Norioka, S., Kawase, I., & Naka, T. (2007). Proteomic analysis of autoantigens associated with systemic lupus erythematosus: Anti-aldolase A antibody as a potential marker of lupus nephritis. Proteomics. Clinical applications, 1(2), 185-91. https://doi.org/10.1002/prca.200600497
Serada, Satoshi, et al. "Proteomic analysis of autoantigens associated with systemic lupus erythematosus: Anti-aldolase A antibody as a potential marker of lupus nephritis." Proteomics. Clinical applications vol. 1,2 (2007): 185-91. doi: https://doi.org/10.1002/prca.200600497
Serada S, Fujimoto M, Takahashi T, He P, Hayashi A, Tanaka T, Hagihara K, Yamadori T, Mochizuki M, Norioka N, Norioka S, Kawase I, Naka T. Proteomic analysis of autoantigens associated with systemic lupus erythematosus: Anti-aldolase A antibody as a potential marker of lupus nephritis. Proteomics Clin Appl. 2007 Feb;1(2):185-91. doi: 10.1002/prca.200600497. Epub 2007 Jan 22. PMID: 21136668.
Copy Download .nbib Format: NLM
Long-Lasting Tumor Response in Patients with Panitumumab Monotherapy for Chemorefractory Metastatic Colorectal Carcinoma - A Report of Two Cases.

Case reports in oncology

Ramadori G, Cameron S, Tschechne B.
PMID: 20740189
Case Rep Oncol. 2010 May 07;3(2):154-159. doi: 10.1159/000312107.

BACKGROUND: Second as well as higher-line therapies have a significant influence on progression-free and overall survival of metastatic colorectal cancer patients. However, treatment of late-stage disease remains suboptimal. Therefore, the introduction of new, effective and well-tolerated agents is of...

Cite
Ramadori G, Cameron S, Tschechne B. Long-Lasting Tumor Response in Patients with Panitumumab Monotherapy for Chemorefractory Metastatic Colorectal Carcinoma - A Report of Two Cases. Case Rep Oncol. 2010;3(2):154-159doi: 10.1159/000312107.
Ramadori, G., Cameron, S., & Tschechne, B. (2010). Long-Lasting Tumor Response in Patients with Panitumumab Monotherapy for Chemorefractory Metastatic Colorectal Carcinoma - A Report of Two Cases. Case reports in oncology, 3(2), 154-159. https://doi.org/10.1159/000312107
Ramadori, G, et al. "Long-Lasting Tumor Response in Patients with Panitumumab Monotherapy for Chemorefractory Metastatic Colorectal Carcinoma - A Report of Two Cases." Case reports in oncology vol. 3,2 (2010): 154-159. doi: https://doi.org/10.1159/000312107
Ramadori G, Cameron S, Tschechne B. Long-Lasting Tumor Response in Patients with Panitumumab Monotherapy for Chemorefractory Metastatic Colorectal Carcinoma - A Report of Two Cases. Case Rep Oncol. 2010 May 07;3(2):154-159. doi: 10.1159/000312107. PMID: 20740189; PMCID: PMC2919992.
Copy Download .nbib Format: NLM
A case report of a patient with hereditary hemorrhagic telangiectasia treated successively with thalidomide and bevacizumab.

Case reports in oncology

Amanzada A, Töppler GJ, Cameron S, Schwörer H, Ramadori G.
PMID: 21611144
Case Rep Oncol. 2010 Sep;3(3):463-70. doi: 10.1159/000323152. Epub 2010 Dec 11.

Hereditary hemorrhagic telangiectasia is characterized by mucocutaneous and visceral telangiectasia and involves several organs with vascular malformations. It is an autosomal dominant disease and is distinguished into three types, which are due to mutations in different genes. The common...

Cite
Amanzada A, Töppler GJ, Cameron S, et al. A case report of a patient with hereditary hemorrhagic telangiectasia treated successively with thalidomide and bevacizumab. Case Rep Oncol. 2010;3(3):463-70doi: 10.1159/000323152.
Amanzada, A., Töppler, G. J., Cameron, S., Schwörer, H., & Ramadori, G. (2010). A case report of a patient with hereditary hemorrhagic telangiectasia treated successively with thalidomide and bevacizumab. Case reports in oncology, 3(3), 463-70. https://doi.org/10.1159/000323152
Amanzada, Ahmad, et al. "A case report of a patient with hereditary hemorrhagic telangiectasia treated successively with thalidomide and bevacizumab." Case reports in oncology vol. 3,3 (2010): 463-70. doi: https://doi.org/10.1159/000323152
Amanzada A, Töppler GJ, Cameron S, Schwörer H, Ramadori G. A case report of a patient with hereditary hemorrhagic telangiectasia treated successively with thalidomide and bevacizumab. Case Rep Oncol. 2010 Sep;3(3):463-70. doi: 10.1159/000323152. Epub 2010 Dec 11. PMID: 21611144; PMCID: PMC3100268.
Copy Download .nbib Format: NLM
The current role of telomerase in the diagnosis of bladder cancer.

Indian journal of urology : IJU : journal of the Urological Society of India

Bravaccini S, Casadio V, Amadori D, Calistri D, Silvestrini R.
PMID: 19468427
Indian J Urol. 2009 Jan;25(1):40-6. doi: 10.4103/0970-1591.45535.

Bladder cancer has an incidence of 15 cases per 100,000 persons in the global population and is the most common tumor of the urinary tract. Imaging techniques, cytoscopy, and cytology are either invasive or not sufficiently accurate to detect...

Cite
Bravaccini S, Casadio V, Amadori D, et al. The current role of telomerase in the diagnosis of bladder cancer. Indian J Urol. 2009;25(1):40-6doi: 10.4103/0970-1591.45535.
Bravaccini, S., Casadio, V., Amadori, D., Calistri, D., & Silvestrini, R. (2009). The current role of telomerase in the diagnosis of bladder cancer. Indian journal of urology : IJU : journal of the Urological Society of India, 25(1), 40-6. https://doi.org/10.4103/0970-1591.45535
Bravaccini, Sara, et al. "The current role of telomerase in the diagnosis of bladder cancer." Indian journal of urology : IJU : journal of the Urological Society of India vol. 25,1 (2009): 40-6. doi: https://doi.org/10.4103/0970-1591.45535
Bravaccini S, Casadio V, Amadori D, Calistri D, Silvestrini R. The current role of telomerase in the diagnosis of bladder cancer. Indian J Urol. 2009 Jan;25(1):40-6. doi: 10.4103/0970-1591.45535. PMID: 19468427; PMCID: PMC2684324.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 206 entries